Oncolytics Biotech Net Income vs. Current Ratio
| ONCY Stock | USD 0.85 0.01 1.16% |
Net Loss | First Reported 2000-03-31 | Previous Quarter -7.3 M | Current Value -9.5 M | Quarterly Volatility 2.8 M |
For Oncolytics Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oncolytics Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oncolytics Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oncolytics Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oncolytics Biotech over time as well as its relative position and ranking within its peers.
Oncolytics |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncolytics Biotech. If investors know Oncolytics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncolytics Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Return On Assets (0.71) | Return On Equity (1.38) |
The market value of Oncolytics Biotech is measured differently than its book value, which is the value of Oncolytics that is recorded on the company's balance sheet. Investors also form their own opinion of Oncolytics Biotech's value that differs from its market value or its book value, called intrinsic value, which is Oncolytics Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncolytics Biotech's market value can be influenced by many factors that don't directly affect Oncolytics Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Oncolytics Biotech Current Ratio vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Oncolytics Biotech's current stock value. Our valuation model uses many indicators to compare Oncolytics Biotech value to that of its competitors to determine the firm's financial worth. Oncolytics Biotech is regarded second in net income category among its peers. It is regarded fourth in current ratio category among its peers . Oncolytics Biotech reported Net Loss of (27.75 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oncolytics Biotech's earnings, one of the primary drivers of an investment's value.Oncolytics Current Ratio vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Oncolytics Biotech |
| = | (27.75 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Oncolytics Biotech |
| = | 10.42 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Oncolytics Current Ratio Comparison
Oncolytics Biotech is currently under evaluation in current ratio category among its peers.
Oncolytics Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Oncolytics Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oncolytics Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Oncolytics Biotech's change in net profit over the period of time. It can combine multiple indicators of Oncolytics Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 544 K | 516.8 K | |
| Operating Income | -33.8 M | -32.1 M | |
| Net Loss | -27.8 M | -29.1 M | |
| Income Tax Expense | 97 K | 92.2 K | |
| Net Loss | -32.4 M | -30.7 M | |
| Income Before Tax | -27.7 M | -29 M | |
| Total Other Income Expense Net | 6.1 M | 6.4 M | |
| Net Loss | -22.4 M | -21.2 M | |
| Net Interest Income | 1.2 M | 1.2 M | |
| Interest Income | 1.2 M | 1.2 M | |
| Change To Netincome | 801.5 K | 1.1 M | |
| Net Loss | (0.41) | (0.43) | |
| Income Quality | 1.03 | 0.71 | |
| Net Income Per E B T | 1.00 | 0.81 |
Oncolytics Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Oncolytics Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oncolytics Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oncolytics Biotech's important profitability drivers and their relationship over time.
Use Oncolytics Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncolytics Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will appreciate offsetting losses from the drop in the long position's value.Oncolytics Biotech Pair Trading
Oncolytics Biotech Pair Trading Analysis
The ability to find closely correlated positions to Oncolytics Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncolytics Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncolytics Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncolytics Biotech to buy it.
The correlation of Oncolytics Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncolytics Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncolytics Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncolytics Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Oncolytics Biotech position
In addition to having Oncolytics Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Rubber and Plastic Products Thematic Idea Now
Rubber and Plastic Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Rubber and Plastic Products theme has 27 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Rubber and Plastic Products Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.